Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results
Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results
Integra LifeSciences said it sees FY24 revenue of $1.609 billion to $1.629 billion versus prior forecast of $1.672 billion to $1.687 billion. The company now sees adjusted earnings of $2.41 to $2.57 per share, versus previous outlook of $3.01 to $3.11 per share.Integra LifeSciences (NASDAQ:IART) reported upbeat second-quarter earnings and lowered its FY24 guidance below estimates on Monday.
英特格拉生命科學（納斯達克：IART）在週一發佈了樂觀的第二季度業績，並將其FY24指導下調到了預估以下。
Integra Lifesciences posted adjusted earnings of 63 cents per share, beating market estimates of 62 cents per share. The company's quarterly sales came in at $418.175 million topping expectations of $413.154 million, according to data from Benzinga Pro.
英特格拉生命科學發佈了每股調整過後的盈利爲63美分，超出市場預估的62美分每股。根據Benzinga Pro的數據，公司季度銷售額爲4181.75萬美元，超過了4131.54萬美元的預期。
"Our second quarter financial performance continues to reflect the persistent market demand for our diversified portfolio and the commitment of our teams," said Jan De Witte, Integra LifeSciences' president and chief executive officer. "Using the learnings from our Boston facility, we are continuing a thorough analysis of our operations and are committed to enhancing the quality, reliability and resilience of our manufacturing operations and supply chain. The reduction in our full-year guidance reflects an updated view of our operational challenges and critical investments in our compliance improvement program that will allow our supply to meet our strong commercial demand strength over time."
英特格拉生命科學公司的總裁兼首席執行官Jan De Witte表示：“我們第二季度的財務表現繼續反映了我們多元化投資組合的持續市場需求和團隊的承諾。通過從我們波士頓工廠中學到的經驗，我們正在繼續對我們的業務進行全面分析，並致力於提高我們製造業運營和供應鏈的質量、可靠性和韌性。我們對全年指導下調反映了我們對運營挑戰和我們合規改進計劃中關鍵性投資的更新看法，這將允許我們的供應在時長內滿足強勁的商業需求強度。”
Integra LifeSciences said it sees FY24 revenue of $1.609 billion to $1.629 billion versus prior forecast of $1.672 billion to $1.687 billion. The company now sees adjusted earnings of $2.41 to $2.57 per share, versus previous outlook of $3.01 to $3.11 per share.
英特格拉生命科學表示，看到FY24的營業收入將爲16.09億至16.29億，低於之前預測的16.72億至16.87億。公司現在看到每股調整後的盈利爲2.41至2.57美元，而之前的預期爲3.01至3.11美元。
Integra LifeSciences shares fell 0.7% to trade at $25.25 on Tuesday.
週二，英特格拉生命科學股價下跌0.7％，交易價爲25.25美元。
These analysts made changes to their price targets on Integra LifeSciences following the announcement.
這些分析師在公告後改變了他們對英特格拉生命科學的價格目標。
- Citigroup analyst Joanne Wuensch downgraded Integra Lifesciences from Neutral to Sell and lowered the price target from $30 to $23.
- Truist Securities analyst Richard Newitter maintained the stock with a Hold, while cutting the price target from $32 to $26.
- JMP Securities analyst David Turkaly maintained Integra Lifesciences with a Market Outperform, while slashing the price target from $40 to $35.
- 花旗集團分析師Joanne Wuensch將英特格拉生命科學的評級從中立下調爲賣出，並將股價目標從30美元降至23美元。
- Truist Securities分析師Richard Newitter維持了股票持有，但將價格目標從32美元降至26美元。
- JMP Securities分析師David Turkaly將英特格拉生命科學的市場表現維持爲跑贏行情，但將股價目標從40美元下調至35美元。
- Top 3 Health Care Stocks You May Want To Dump This Quarter
- 可能想要在本季度拋售的前3家醫療保健股票
譯文內容由第三人軟體翻譯。
